Loxo Oncology is dedicated to the discovery and development of targeted therapies in the treatment of cancer. Our research focuses on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect—aiming to maximally inhibit the intended target. We aim to develop purpose-built, highly selective therapies designed to inhibit cancer-driving molecular targets in genetically defined pediatric and adult patient populations. Our pipeline and clinical development programs feature highly selective compounds under evaluation in studies worldwide